Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Regulation

FDA approval of Regeneron’s Evkeeza brings new drug class to HoFH patients

By Sandi Wong, Assistant Editor
February 12, 2021 2:06 AM UTC

Regeneron’s Evkeeza evinacumab-dgnb gained FDA approval Thursday as the first ANGPTL3 inhibitor to treat homozygous familial hypercholesterolemia, offering a new mechanism of action to patients who don’t respond to statins or PCSK9 therapy. 

The mAb is approved as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat HoFH patients ages 12 and older. The ultra-rare genetic disorder affects about 1,300 U.S. patients...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Regeneron Pharmaceuticals Inc.

BCIQ Target Profiles

Angiopoietin-like 3 (ANGPTL3)